San Diego-based Trius Therapeutics has filed for an IPO, saying Friday that it is looking to raise $86.25M in an offering on the Nasdaq Global Market. According to the firm's filing, it has applied to trade under the symbol TSRX. The IPO is being underwritten by Credit Suisse, Piper Jaffray, Canaccord Adams, and JMP Securities. Trius Therapeutics is a biopharmaceuticals firm focused on developing new antibiotics, with a lead compound focused on treating methicillin-resistant Staphylococcus aureus (MRSA). Trius is backed by Sofinnova Ventures, InterWest Partners, Versant Ventures, Prism Venture Partners, and Kleiner Perkins Caufield & Byers, among others.
Top NewsMonday, November 9, 2009
Trius Therapeutics Files For IPO